HK1257229A1 - Cck2r-药物偶联物 - Google Patents
Cck2r-药物偶联物 Download PDFInfo
- Publication number
- HK1257229A1 HK1257229A1 HK18116265.4A HK18116265A HK1257229A1 HK 1257229 A1 HK1257229 A1 HK 1257229A1 HK 18116265 A HK18116265 A HK 18116265A HK 1257229 A1 HK1257229 A1 HK 1257229A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cck2r
- drug conjugates
- pertains
- disclosure
- drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205411P | 2015-08-14 | 2015-08-14 | |
| US201562205411P | 2015-08-14 | ||
| US201562261227P | 2015-11-30 | 2015-11-30 | |
| US201562261227P | 2015-11-30 | ||
| US201662323287P | 2016-04-15 | 2016-04-15 | |
| US201662323287P | 2016-04-15 | ||
| PCT/US2016/046292 WO2017030859A1 (en) | 2015-08-14 | 2016-08-10 | Cck2r-drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1257229A1 true HK1257229A1 (zh) | 2019-10-18 |
Family
ID=58051970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18116265.4A HK1257229A1 (zh) | 2015-08-14 | 2016-08-10 | Cck2r-药物偶联物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10500286B2 (https=) |
| EP (1) | EP3334447A4 (https=) |
| JP (1) | JP2018525399A (https=) |
| CA (1) | CA2995371A1 (https=) |
| HK (1) | HK1257229A1 (https=) |
| WO (1) | WO2017030859A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| KR20180090290A (ko) | 2015-12-04 | 2018-08-10 | 시애틀 지네틱스, 인크. | 사차화 튜불리신 화합물들의 컨쥬게이트들 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| AU2021466987B2 (en) * | 2021-09-28 | 2025-11-20 | Paul Scherrer Institut | Method for predicting the response of a patient diagnosed with cancer to treatment and/or imaging with a compound targeting cck2-r, and compound for use in methods of selectively treating and/or imaging cancer |
| CN120554245B (zh) * | 2025-07-30 | 2026-02-27 | 辽宁众辉生物科技有限公司 | 一种氟吡菌酰胺中间体n-乙酰氧基甲基-2-三氟甲基苯甲酰胺的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776814B2 (en) * | 2002-07-09 | 2010-08-17 | R&D-Biopharmaceuticals Gmbh | Tubulysin conjugates |
| US8431714B2 (en) * | 2007-04-16 | 2013-04-30 | University Of Southern California | Synthesis of drug conjugates via reaction with epoxide-containing linkers |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
-
2016
- 2016-08-10 HK HK18116265.4A patent/HK1257229A1/zh unknown
- 2016-08-10 JP JP2018507646A patent/JP2018525399A/ja active Pending
- 2016-08-10 WO PCT/US2016/046292 patent/WO2017030859A1/en not_active Ceased
- 2016-08-10 CA CA2995371A patent/CA2995371A1/en not_active Abandoned
- 2016-08-10 EP EP16837521.0A patent/EP3334447A4/en not_active Withdrawn
- 2016-08-10 US US15/751,633 patent/US10500286B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017030859A1 (en) | 2017-02-23 |
| EP3334447A1 (en) | 2018-06-20 |
| CA2995371A1 (en) | 2017-02-23 |
| JP2018525399A (ja) | 2018-09-06 |
| EP3334447A4 (en) | 2019-07-24 |
| US20180228909A1 (en) | 2018-08-16 |
| US10500286B2 (en) | 2019-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201803042PA (en) | Anti-tim-3 antibodies | |
| EP3154574A4 (en) | Homogenous antibody drug conjugates via enzymatic methods | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| EP3315608A4 (en) | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof | |
| MX2019007020A (es) | Anticuerpos il-11. | |
| MY193806A (en) | Affinity-oligonucleotide conjugates and uses thereof | |
| EP3334500A4 (en) | MULTILIGAND-ACTIVE CONJUGATES AND USES THEREOF | |
| TN2017000246A1 (en) | Anti-c10orf54 antibodies and uses thereof | |
| EP3207147A4 (en) | Bipartite and tripartite signaling immune cells | |
| EP3186277A4 (en) | Antibodies, compositions, and uses | |
| EP3100731A4 (en) | Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof | |
| EP3253212A4 (en) | Antibody drug conjugates | |
| EP3250238A4 (en) | Antibody drug conjugates | |
| WO2015168019A3 (en) | Anti-ptk7 antibody-drug conjugates | |
| EP3129048A4 (en) | Antibodies, pharmaceutical compositions and uses thereof | |
| EP3216238A4 (en) | Group communication function for delivering group communication messages in communication netwoks | |
| EP3251698A4 (en) | Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof | |
| EP3359193A4 (en) | NOVEL CARBOHYDRATIC ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| MX2017009937A (es) | Cepas fungicas y metodos de uso. | |
| EP3186217A4 (en) | Polyethers, polyamines, polythioethers, and methods for making same | |
| GB201614162D0 (en) | Antibodies, uses thereof and conjugates thereof | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| EP3148565A4 (en) | Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof | |
| AU2016289474B2 (en) | HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents | |
| AU2015315168A8 (en) | Targeted mutagenesis in spirulina |